Faculty Collaboration Database

Cardiovascular actions of a new dihydropyridine calcium antagonist, 8363-S: comparison with nifedipine and nicardipine in awake, unsedated dogs. J Cardiovasc Pharmacol 1987 Jul;10(1):30-7

Date

07/01/1987

Pubmed ID

2441151

DOI

10.1097/00005344-198707000-00005

Scopus ID

2-s2.0-0023251434 (requires institutional sign-in at Scopus site)   4 Citations

Abstract

The systemic and coronary hemodynamic actions of a new dihydropyridine, 8363-S, were compared with nifedipine and nicardipine in conscious, instrumented dogs following intravenous and oral administration. All agents produced similar reductions in arterial and ventricular pressures and increases in heart rate, dP/dt, and coronary blood flow velocity, following intravenous infusion. Following oral administration, all agents had qualitatively similar actions; however, there was a marked difference in potency. 8363-S was found to be most potent in that 0.25 mg/kg produced equivalent or larger changes from control than 0.5 mg/kg nifedipine or 1.0 mg/kg nicardipine. Furthermore, 8363-S had a longer duration of action following oral administration. The results suggest that important differences in bioavailability exist amongst dihydropyridines which may have important therapeutic implications.

Author List

Wynsen JC, Shimshak TM, Preuss KC, Hardman HF, Warltier DC

Author

David C. Warltier PhD Emeritus Professor in the Anesthesiology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Administration, Oral
Animals
Calcium Channel Blockers
Cardiovascular System
Dihydropyridines
Dogs
Dose-Response Relationship, Drug
Hemodynamics
Injections, Intravenous
Nicardipine
Nifedipine
Pyridines